Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases

被引:1
作者
Aline Freyssin [1 ]
Guylène Page [1 ]
Bernard Fauconneau [1 ]
Agnès Rioux Bilan [1 ]
机构
[1] University of Poitiers, EA3808 NEUVACOD (Neurovascular Unit and Cognitive Disorders)
关键词
natural polyphenols; protein aggregates; Alzheimer’s disease; amyloid peptide; amyloid plaques; hyperphosphorylated tau; Parkinson’s disease; α-synuclein; synphilin-1;
D O I
暂无
中图分类号
R749.16 [];
学科分类号
100203 ;
摘要
Alzheimer’s and Parkinson’s diseases are the most common neurodegenerative diseases. They are characterized by protein aggregates and so can be considered as prion-like disease. The major components of these deposits are amyloid peptide and tau for Alzheimer’s disease, α-synuclein and synphilin-1 for Parkinson’s disease. Drugs currently proposed to treat these pathologies do not prevent neurodegenerative processes and are mainly symptomatic therapies. Molecules inducing inhibition of aggregation or disaggregation of these proteins could have beneficial effects, especially if they have other beneficial effects for these diseases. Thus, several natural polyphenols, which have antioxidative, anti-inflammatory and neuroprotective properties, have been largely studied, for their effects on protein aggregates found in these diseases, notably in vitro. In this article, we propose to review the significant papers concerning the role of polyphenols on aggregation and disaggregation of amyloid peptide, tau, α-synuclein, synphilin-1, suggesting that these compounds could be useful in the treatments in Alzheimer’s and Parkinson’s diseases.
引用
收藏
页码:955 / 961
页数:7
相关论文
共 50 条
  • [41] Mitochondria in the pathophysiology of Alzheimer's and Parkinson's diseases
    Onyango, Isaac G.
    Khan, Shaharyar M.
    Bennett, James P., Jr.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2017, 22 : 854 - 872
  • [42] Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms
    Chen, Merry
    Mor, Danielle E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [43] Sleep Disturbances in Alzheimer's and Parkinson's Diseases
    Rothman, Sarah M.
    Mattson, Mark P.
    NEUROMOLECULAR MEDICINE, 2012, 14 (03) : 194 - 204
  • [44] Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease
    Cohen, Mark
    Appleby, Brian
    Safar, Jiri G.
    PRION, 2016, 10 (01) : 9 - 17
  • [45] Sleep Disturbances in Alzheimer’s and Parkinson’s Diseases
    Sarah M. Rothman
    Mark P. Mattson
    NeuroMolecular Medicine, 2012, 14 : 194 - 204
  • [46] Prion-like propagation of cytosolic protein aggregates Insights from cell culture models
    Krammer, Carmen
    Schaetzl, Hermann M.
    Vorberg, Ina
    PRION, 2009, 3 (04) : 206 - 212
  • [47] Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases
    Sinnige, Tessa
    Stroobants, Karen
    Dobson, Christopher M.
    Vendruscolo, Michele
    QUARTERLY REVIEWS OF BIOPHYSICS, 2020, 49
  • [48] Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases
    Claus, JJ
    Mohr, E
    ACTA NEUROLOGICA SCANDINAVICA, 1996, 93 (05): : 346 - 351
  • [49] Mitochondrial DNA in pathogenesis of Alzheimer's and Parkinson's diseases
    Maruszak, Aleksandra
    Gaweda-Walerych, Katarzyna
    Soltyszewski, Ireneusz
    Kekanowski, Cezary
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2006, 66 (02) : 153 - 176
  • [50] Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases
    Hernando, Sara
    Gartziandia, Oihane
    Herran, Enara
    Luis Pedraz, Jose
    Igartua, Manoli
    Maria Hernandez, Rosa
    NANOMEDICINE, 2016, 11 (10) : 1267 - 1285